Related Experiment Video

Updated: Oct 1, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K

MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy

Aysooda Hosseinzadeh1, Parnaz Merikhian1, Nazanin Naseri1

  • 1Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, South Gandi, Vanak Squar, 1517964311, Tehran, Iran.

Cancer Cell International
|March 6, 2022
PubMed

Insights

Mucin 1 (MUC1) is identified as a key factor in trastuzumab resistance for HER2-positive breast cancer. Targeting MUC1 shows promise for overcoming this resistance and improving cancer therapy outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Trastuzumab is a successful treatment for HER2-positive breast cancer.
  • Therapeutic resistance remains a significant challenge in cancer treatment.
  • Understanding resistance mechanisms is crucial for developing effective therapies.

Purpose of the Study:

  • To review mechanisms of trastuzumab resistance in breast cancer.
  • To explore Mucin 1 (MUC1) as a potential therapeutic target.
  • To discuss how targeting MUC1 can overcome trastuzumab resistance.

Main Methods:

  • Literature review of resistance mechanisms to trastuzumab.
  • Analysis of MUC1's role in cancer cell signaling pathways.
  • Evaluation of MUC1 as a target for overcoming resistance.

Main Results:

  • MUC1, particularly MUC1-Cytoplasmic Domain (MUC1-CD), accelerates trastuzumab resistance.
  • Silencing MUC1 increases sensitivity of HER2+ cells to trastuzumab.
  • MUC1 interacts with oncogenic pathways like HER2, β-catenin, and NF-κB.

Conclusions:

  • MUC1 plays a significant role in trastuzumab resistance.
  • Targeting MUC1 presents a viable strategy to circumvent resistance.
  • Further research into MUC1-targeted therapies could improve breast cancer treatment.
Keywords:
CancerDrug ResistanceHER2MUC1Trastuzumab

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K